Literature DB >> 2355800

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

T Thomsen1, H Kewitz.   

Abstract

We investigated the inhibition of human cholinesterases by galanthamine, an alkaloid of the common snowdrop (galanthus nivalis). In vitro, the compound showed potent enzyme inhibition and 50-fold selectivity for acetylcholinesterase (EC 3.1.1.7) as opposed to butyrylcholinesterase (EC 3.1.1.8). There was no difference between enzyme inhibition by galanthamine in whole blood and separated fractions of plasma and erythrocytes. We conclude that galanthamine does not accumulate in large amounts in red blood cells. In vivo, administration of galanthamine in a healthy volunteer and in a patient who underwent long-term treatment confirmed the selectivity of galanthamine for acetylcholinesterase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355800     DOI: 10.1016/0024-3205(90)90429-u

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  32 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.

Authors:  S Rossenu; C Gaynor; A Vermeulen; A Cleton; A Dunne
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-09       Impact factor: 2.745

3.  Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

Authors:  Edson X Albuquerque; Edna F R Pereira; Yasco Aracava; William P Fawcett; Maristela Oliveira; William R Randall; Tracey A Hamilton; Robert K Kan; James A Romano; Michael Adler
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-16       Impact factor: 11.205

4.  Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

Authors:  Debby Van Dam; Dorothee Abramowski; Matthias Staufenbiel; Peter Paul De Deyn
Journal:  Psychopharmacology (Berl)       Date:  2005-01-15       Impact factor: 4.530

5.  Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

Authors:  T Thomsen; U Bickel; J P Fischer; H Kewitz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  An LC-MS/MS method for the simultaneous determination of lycorine and galanthamine in rat plasma and its application to pharmacokinetic study of Lycoris radiata extract in rats.

Authors:  Xin Zhou; Yue-Bin Liu; Shan Huang; Ying Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 7.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

8.  Galanthamine in Alzheimer's disease : a new alternative to tacrine?

Authors:  M Rainer
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 9.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

Authors:  Gordon Wilcock; Ian Howe; Hilary Coles; Sean Lilienfeld; Luc Truyen; Young Zhu; Roger Bullock; Paul Kershaw
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.